Avalyn Pharma Inc(AVLN)
$30.28-0.31 (-1.01%)
AVLN
Avalyn Pharma Inc financials statements
$30.28
At close:-0.31 (-1.01%)
Want to see AVLN full AI Analyst Report?
Avalyn Pharma Inc (AVLN) Ratios
8 Followers
Avalyn Pharma Inc Ratios
AVLN's free cash flow for Q3 2026 was $-26.34M. For the 2026 fiscal year, AVLN's free cash flow was decreased by $-72.00K and operating cash flow was $-26.27M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 |
|---|---|---|
| Liquidity Ratios | ||
| Current Ratio | 10.19 | ― |
| Quick Ratio | 10.19 | ― |
| Cash Ratio | 3.71 | ― |
| Solvency Ratio | -0.22 | ― |
| Operating Cash Flow Ratio | -5.78 | ― |
| Short-Term Operating Cash Flow Coverage | 0.00 | ― |
| Net Current Asset Value | $ -243.98M | ― |
| Leverage Ratios | ||
| Debt-to-Assets Ratio | 0.01 | ― |
| Debt-to-Equity Ratio | -0.01 | ― |
| Debt-to-Capital Ratio | -0.01 | ― |
| Long-Term Debt-to-Capital Ratio | 0.00 | ― |
| Financial Leverage Ratio | -0.62 | ― |
| Debt Service Coverage Ratio | 0.00 | ― |
| Interest Coverage Ratio | 0.00 | ― |
| Debt to Market Cap | 0.00 | ― |
| Interest Debt Per Share | 0.04 | ― |
| Net Debt to EBITDA | 0.56 | ― |
| Profitability Margins | ||
| Gross Profit Margin | 0.00% | ― |
| EBIT Margin | 0.00% | ― |
| EBITDA Margin | 0.00% | ― |
| Operating Profit Margin | 0.00% | ― |
| Pretax Profit Margin | 0.00% | ― |
| Net Profit Margin | 0.00% | ― |
| Continuous Operations Profit Margin | 0.00% | ― |
| Net Income Per EBT | 100.00% | ― |
| EBT Per EBIT | 93.33% | ― |
| Return on Assets (ROA) | -57.23% | ― |
| Return on Equity (ROE) | 35.70% | ― |
| Return on Capital Employed (ROCE) | -67.73% | ― |
| Return on Invested Capital (ROIC) | -67.51% | ― |
| Return on Tangible Assets | -57.23% | ― |
| Earnings Yield | -6.91% | ― |
| Efficiency Ratios | ||
| Receivables Turnover | 0.00 | ― |
| Payables Turnover | 0.00 | ― |
| Inventory Turnover | 0.00 | ― |
| Fixed Asset Turnover | 0.00 | ― |
| Asset Turnover | 0.00 | ― |
| Working Capital Turnover Ratio | 0.00 | ― |
| Cash Conversion Cycle | 0.00 | ― |
| Days of Sales Outstanding | 0.00 | ― |
| Days of Inventory Outstanding | 0.00 | ― |
| Days of Payables Outstanding | 0.00 | ― |
| Operating Cycle | 0.00 | ― |
| Cash Flow Ratios | ||
| Operating Cash Flow Per Share | -1.95 | ― |
| Free Cash Flow Per Share | -1.96 | ― |
| Dividend Paid and CapEx Coverage Ratio | -236.87 | ― |
| Capital Expenditure Coverage Ratio | -236.87 | ― |
| Operating Cash Flow Coverage Ratio | -48.82 | ― |
| Operating Cash Flow to Sales Ratio | 0.00 | ― |
| Free Cash Flow Yield | -6.64% | ― |
| Valuation Ratios | ||
| Price-to-Earnings (P/E) Ratio | -14.46 | ― |
| Price-to-Sales (P/S) Ratio | 0.00 | ― |
| Price-to-Book (P/B) Ratio | -5.17 | ― |
| Price-to-Free Cash Flow (P/FCF) Ratio | -15.07 | ― |
| Price-to-Operating Cash Flow Ratio | -15.13 | ― |
| Price-to-Earnings Growth (PEG) Ratio | -0.20 | ― |
| Enterprise Value Multiple | -12.96 | ― |
| Enterprise Value | 1.18B | ― |
| EV to EBITDA | -12.96 | ― |
| EV to Sales | 0.00 | ― |
| EV to Free Cash Flow | -14.45 | ― |
| EV to Operating Cash Flow | -14.51 | ― |
| Tangible Book Value Per Share | -5.71 | ― |
| Shareholders’ Equity Per Share | -5.71 | ― |
| Tax and Other Ratios | ||
| Effective Tax Rate | 0.00 | ― |
| Revenue Per Share | 0.00 | ― |
| Net Income Per Share | -2.04 | ― |
| Tax Burden | 1.00 | ― |
| Interest Burden | 0.93 | ― |
| Research & Development to Revenue | 0.00 | ― |
| SG&A to Revenue | 0.00 | ― |
| Stock-Based Compensation to Revenue | 0.00 | ― |
| Income Quality | 0.96 | ― |
Currency in USD
